Recent advances in nuclear medicine are reshaping the diagnostic and therapeutic landscape of oncology. This session will provide a concise overview of current progress in the field, the challenges posed by heterogeneous HTA evaluations and workforce limitations, and the evolving role of patients in guiding care pathways.
In addition, emerging evidence from neuroendocrine tumour management will be highlighted, offering insights into how innovative approaches are being implemented in real-world settings. Together, these perspectives will help outline the opportunities and priorities for the future development of nuclear medicine.